Biodesix named to Inc. 500|5000 Fastest-Growing Private Companies list
Biodesix recently added Biognosys' Proteomics to their capabiltites.
HealthNet now covers Biodesix' VeriStrat test
Biodesix raises follow-on series E financing
Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.
Biodesix' VeriStrat test is covered by Cigna
Biodesix' VeriStrat test has won approval from CareFirst BlueCross BlueShield
The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.
In addition to the $15 million of series shares in 2013 and 2014, Biodesix brought in another $12 million, for total proceeds of $27 million from the sale.